Novo Nordisk Q1 2026: Strong Wegovy Performance Drives Guidance Raise, but Pricing Pressure Remains Key Risk

What happened

Novo Nordisk reported Q1 adjusted operating profit of DKK 32,858 million, driven by strong Wegovy sales and International Operations growth, leading management to raise full-year guidance. However, the earnings beat does not resolve the core tension in the equity narrative: U.S. net pricing is under structural pressure from cash-pay discounting, CMS access pilots, and the Jan 1, 2027 list-price reset. The master report maintains a WAIT rating with a $48 base case, noting that positive volume momentum from policy programs could offset price declines if discounting remains time-boxed. Conversely, the risk of permanent discounting and competitive pressure from Lilly's cash-pay moves (LillyDirect) could compress margins and drive downside toward $34. Investors should monitor the June 30 expiry of NovoCare's $199 intro offer and July's CMS Bridge implementation as key catalysts.

Implication

The Q1 beat and guidance raise provide near-term support, but the structural pricing headwinds in the U.S. remain unresolved. The master report's base case of $48 relies on volume growth from CMS programs compensating for mid-single-digit price declines. However, if Novo extends the $199 intro offer beyond June 30 (signaling permanent discounting) or if CMS economics prove margin-dilutive, the bear case of $34 becomes more likely. Investors should wait for evidence that discounting is staying time-boxed and that CMS volume translates to stable net pricing. The attractive entry point of $38 offers a margin of safety only if these conditions materialize.

Thesis delta

The Q1 results do not alter the core thesis that U.S. pricing dynamics are the dominant risk; the guidance raise is positive but does not shift the WAIT rating. The key catalyst remains the June 30 decision on the $199 intro offer and subsequent CMS implementation.